Arterial Stiffness as Surrogate End Point

Stéphane Laurent; Marie Briet; Pierre Boutouyrie

doi:10.1161/hypertensionaha.112.194456

June 27, 2012HypertensionOpen Access

Arterial Stiffness as Surrogate End Point

View Full Paper

Ask AI

Bookmark

Share

Key Points

To examine the roles of imaging biomarkers and surrogate end points, focusing on whether arterial stiffness can serve as a validated surrogate end point for cardiovascular events.
Reviewed clinical evidence contrasting traditional risk scores with novel circulating and imaging biomarkers in asymptomatic hypertensive individuals.
Evaluated methodological frameworks and trial designs required to test whether normalizing arterial stiffness improves clinical outcomes over standard care.
Arterial stiffness provides superior risk reclassification compared with circulating biomarkers, particularly among asymptomatic individuals categorized at intermediate risk.
Confirmation of arterial stiffness as a definitive surrogate end point remains limited, requiring randomized clinical trials showing that targeted destiffening directly reduces hard cardiovascular events.

Design

Review

Implication

Supports arterial stiffness investigation as biomarker in primary prevention; leaves open its validation as surrogate endpoint pending prospective trials.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Laurent et al. (2012) studied this question.

synapsesocial.com/papers/6a87194ba131ca6707155d34 https://doi.org/10.1161/hypertensionaha.112.194456

View Full Paper

Ask AI

Bookmark

Share

Arterial Stiffness as Surrogate End Point

Key Points

Implication

Abstract

Discussion

Cite This Study

Arterial Stiffness as Surrogate End Point

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading